fbpx

Nyheder

Lundbeckfonden Ventures nyheder

  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf® and has randomized over 540 patients at approximately 90 clinical sites around the world....
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the launch of a new corporate web site. The new web site aims to update the BONESUPPORT brand while providing increased educational and clinical CERAMENTT content to an expanding audience. “Our business has...
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world populationParis, March 22, 2012 – Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a...
  Viaskin Peanut, the first epicutaneous skin patch for the treatment of peanut allergy, is recognized as a unique and promising desensitization product   BAGNEUX, France, February 28, 2012 – DBV Technologies announced today that it has received Fast Track Designation” for the Clinical Development Program of its Viaskin® Peanut, a product designed for the...
  LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ — Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. The financing was led...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-TacroT in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. APD421...
  Lund, Sweden; Lloyd Diamond has been recruited CEO of BONESUPPORT – the Swedish medical technology company with a revolutionary orthobiologic platform for treatment of osteoporotic fractures and deep bone infections. Mr. Diamond replaces Dr. Fredrik Lindberg, the co-founder and present CEO, who will remain in the company as Chief Scientific Officer. By the recruitment...
1 61 62 63 64 65 66

Lundbeckfonden Ventures

Nyheder

VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
8. juli 2020
scPharmaceuticals Announces FUROSCIX® NDA Resubmission
3. juli 2020
Acacia Pharma Group PLC – Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedatio
3. juli 2020